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Abstract
Background: Human immunoglobulin G (IgG) plays an important role in mediating protective immune responses
to malaria. Although human serum immunoglobulin A (IgA) is the second most abundant class of antibody in the
circulation, its contribution, if any, to protective responses against malaria is not clear.
Results: To explore the mechanism(s) by which IgA may mediate a protective effect, we generated fully human
IgA specific for the C-terminal 19-kDa region of Plasmodium falciparum merozoite surface protein 1 (PfMSP119), a
major target of protective immune responses. This novel human IgA bound antigen with an affinity comparable to
that seen for an epitope-matched protective human IgG1. Furthermore, the human IgA induced significantly
higher NADPH-mediated oxidative bursts and degranulation from human neutrophils than the epitope-matched
human IgG1 from which it was derived. Despite showing efficacy in in vitro functional assays, the human IgA failed
to protect against parasite challenge in vivo in mice transgenic for the human Fca receptor (FcaRI/CD89). A
minority of the animals treated with IgA, irrespective of FcaRI expression, showed elevated serum TNF-a levels and
concomitant mouse anti-human antibody (MAHA) responses.
Conclusions: The lack of protection afforded by MSP119-specific IgA against parasite challenge in mice transgenic
for human FcaRI suggests that this antibody class does not play a major role in control of infection. However, we
cannot exclude the possibility that protective capacity may have been compromised in this model due to rapid
clearance and inappropriate bio-distribution of IgA, and differences in FcaRI expression profile between humans
and transgenic mice.
Background
There is increasing interest in exploring the therapeutic
potential of alternative antibody (Ab) classes to IgG,
which to date has been the most popular choice, with
over 160 examples currently in clinical trials for the
treatment of diverse cancers, infectious diseases and
auto-immune conditions [1,2]. We recently developed a
novel humanized mouse model to show that human
IgG1 specific for Plasmodium falciparum merozoite sur-
face protein 1-19 (PfMSP119) could protect animals
from malaria in passive transfer experiments [3].
However there are numerous drawbacks to using IgG-
based therapies in malaria, including competition for
FcR binding, from high levels of parasite-induced non-
specific IgG [4], that warrant the exploration of other
serum Ab classes for use against infections of blood.
FcaRI (CD89) targeting with IgA could offer potential
for controlling malaria with therapeutic antibodies [5].
Unlike IgM, IgG and IgE, which are implicated in
immune evasion [6], placental malaria [7] and severe
malaria respectively [8], IgA has not been implicated in
malaria pathology, arguing for its consideration in Ab
therapy. Although a direct role for murine IgA in killing
of rodent malaria parasites has not been investigated in
vivo because mice lack an equivalent of human FcaRI,
Plasmodium-specific IgA has been detected at high
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humans from endemic areas.
Ligation of the myeloid FcaRI induces cytokine release
and can stimulate a respiratory burst [12,13], and FcaRI is
better than FcgRs at triggering lysis of Ab-targeted tumors
as well as phagocytosis of pathogens coated with Abs,
both in humans and mice [13,14]. Human FcaRI is
expressed on the majority of white blood cells, including
neutrophils, monocytes, macrophages, eosinophils, plate-
lets and NK cells, suggesting it to be an ideal target for
systemic IgA-mediated therapy [4,5,13,15,16]. The finding
that FcaRI is a discrete modulator of the immune system
mediating both anti- and pro-inflammatory functions indi-
cates that further exploration of the role of human IgA in
malaria is necessary [17]. We recently described a manda-
tory role for human FcaRI in mediating protection from
tuberculosis using recombinant human IgA [18].
To address the role of human IgA in malaria, we gen-
erated a recombinant IgA recognizing the PfMSP119 epi-
tope, matched to a human IgG1 shown previously to
transfer passive protection in the FcgRI (CD64) trans-
genic mouse model [3]. This recombinant IgA was then
tested in passive transfer experiments for efficacy in
controlling malaria in vivo in human FcaRI (CD89)
transgenic mice.
Results
1. Characterization of PfMSP119-specific human IgA
PfMSP119-specific human IgA isolated from HEK-293T
transfectant culture supernatants by affinity-chromato-
graphy appeared pure (Figure 1). It ran ahead of recom-
binant anti-NIP polymeric IgA2 and IgM under native
conditions (Figure 1A), suggesting that it is mainly
monomeric, a conclusion supported by size-exclusion
chromatographic analysis (data not shown). The anti-
NIP antibodies are in polymeric form having been pro-
duced in J-chain expressing transfectants. On reducing
SDS-PAGE gels, the recombinant IgA resolved into
heavy and light chain bands of the anticipated molecular
mass (Figure 1B). The heavy chain was recognized by an
isotype-specific Ab. The recombinant human IgA recog-
nized a P. falciparum MSP119-GST fusion protein in
ELISAs and by indirect IFA produced a characteristic
pattern of MSP1 reactivity in schizonts, merozoites, and
ring-stage parasites from P. falciparum and Plasmodium
berghei parasites transgenic for PfMSP119 (data not
shown). Importantly, surface plasmon resonance (SPR)
analysis revealed no reduction in affinity for PfMSP119
when compared with the parental IgG1 antibody (Table
1). The binding constants remain essentially the same,
and although the affinity for PfMSP119 is less than that
of a well characterized mouse monoclonal antibody
(mAb) 12.10 specific for PfMSP119 (Table 1), it is still
appreciable.
Figure 1 Characterization of purified recombinant PfMSP119-
specific human IgA.5μg purified recombinant Abs were run under
(A) non-denaturing (native) conditions on 6% acrylamide Tris-glycine
gels (Novex) or under (B) denaturing reducing conditions on NuPAGE
4-12% Bis-Tris gradient SDS gels (Novex). In the former, anti-NIP IgA2
(AbD Serotec, Kidlington, UK) and anti-NIP IgM (AbD Serotec) were
included as polymeric controls. In the latter, gels were either stained
with Coomassie or transferred to nitrocellulose and probed with anti-
human IgA or anti-mouse IgG-Fc reagents, and lanes containing both
IgA and the anti-FcaRI mAb 2H8 were included. The IgA is recognized
by anti-human IgA-specific reagents but not by anti-mouse IgG-Fc
reactive Abs that only recognize mAb 2H8.
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adenine dinucleotide phosphate (NADPH) oxidase
activation through FcaRI cross-linking
We next assessed the ability of this novel IgA to interact
with human FcaRI and induce NADPH oxidase activa-
tion (respiratory burst) and degranulation in human
blood neutrophils (Figure 2). For neutrophils, luminol
chemiluminescence provides a read out of NADPH oxi-
dase activation and myeloperoxidase release [12,13].
When attached to PfMSP119-GST-coated plates, the
human IgA induced significantly greater respiratory
bursts than if the IgA was coated directly to the bottom
of the plate in the absence of antigen (Figure 2), sug-
gesting that binding to antigen allows the IgA to be pre-
sented to neutrophil FcaRI in an optimal configuration
for receptor cross-linking and triggering of functional
responses. We have observed that this IgA induces
greater respiratory bursts from human neutrophils than
the epitope-matched humanI g G 1f r o mw h i c ht h i sA b
was derived [3]. This ability of human IgA to
outperform human IgG1 at inducing free oxygen radi-
cals and activation of human neutrophils has also been
observed for human IgA recognizing the homologous
antigen from Plasmodium yoelii [13].
3. Passive transfer of human IgA into wild type or human
FcaRI (CD89) transgenic mice has no effect on the course
of a malaria infection
Because FcaRI is absent in mice due to a translocation
event in the leukocyte receptor complex, we tested the
ability of the human IgA to protect from malaria using
human FcaRI transgenic mice [19,20]. These mice have
been used to show protection from mucosally adminis-
tered pathogens but have not been directly investigated
in relation to blood parasites or in the context of
human IgA administered systemically [21,22]. Blood
granulocytes and a proportion of monocytes from these
transgenic mice constitutively express functional human
FcaRI and bind human IgA (Additional file 1, Figure
S1). In vivo experiments with P. berghei transgenic for
PfMSP119 highlighted that three intraperitoneal (i.p.)
inoculations of IgA (total dose of 1.5 mg Ab per mouse)
w a su n a b l et os u p p r e s sal e t h a lb l o o ds t a g ec h a l l e n g e
infection in these animals in contrast to previous obser-
vations with the epitope-matched human IgG1 passively
administered into human FcgRI (CD64) transgenic ani-
mals [3] (Figure 3).
4. Passive transfer of PfMSP119-specific human IgA1 into
mice induces TNF-a and mouse anti-human antibody
(MAHA) responses in some animals
We observed that animals passively immunised with
PfMSP119-specific human IgA by the i.p. route showed
greater adverse clinical signs according to the Labora-
tory Animal Science Association (LASA) indices, includ-
ing severe piloerection & lethargy, after challenge with
malaria parasites than control groups of animals. To
investigate the underlying basis for these observed detri-
mental effects of the passively transferred human IgA
we analyzed serum cytokines responses in all the ani-
mals using the cytometric bead array mouse Th1/Th2
10plex kit (Bender Medsystems) on day 10 post-chal-
lenge when all mice were killed. We observed signifi-
cantly elevated levels of TNF-a in animals treated with
human IgA compared with control animals given PBS,
irrespective of genetic background (Figure 4), although
extreme levels of TNF-a were only seen in four of the
fourteen mice tested. The difference in TNF-a levels
between the transgenic and non-transgenic groups
administered IgA was not statistically significant (Figure
4). No significant differences over baseline levels of IL-4,
IL-10, IFN-g, IL-6, IL-17, GM-CSF were observed
between the groups, although IL-2 and IL-1a were
raised in animals given IgA when compared with PBS
Table 1 Analysis of the binding properties of PfMSP119-
specific human IgA (C1), human IgG1 (C1) and mouse
mAb 12.10 to immobilized GST-PfMSP119 by SPR.
Kass Kdiss Kd
(M
-1 sec
-1) (sec
-1) (M)
mAb 12.10 5.37 × 10
5 5.5 × 10
-6 1×1 0
-11
IgG1 (C1) 4.4 × 10
3 1.0 × 10
-4 2.3 × 10
-8
IgA (C1) 6.5 × 10
3 1.7 × 10
-4 2.6 × 10
-8
(Kd =K diss/Kass)
Methodology described in refs [3,13].
Figure 2 Recombinant human PfMSP119-specific IgA is
functional. Stimulation of neutrophil NADPH oxidative bursts using
50 μg of IgA attached to GST-PfMSP119-coated microtiter plates
(open squares), or 50 μg of IgA attached directly to the bottom of
the plate (open triangles) or no Ab (open curcles). Data are
presented as mean chemiluminescence (CL; arbitary units) from
triplicate wells using neutrophils from a single human donor as
previously described [3,12,13].
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mouse mAb that binds to human FcaRI blocking the
human IgA binding site [23], at the time of IgA delivery,
failed to dramatically alter the course of parasitemia
(Figure 3) or the development of TNF-a responses (not
shown). The induction of elevated TNF-a was therefore
not dependent on the presence of the human FcaRI
transgene, but more likely due to some uncharacterized
effect of the PfMSP119-specific IgA, a result supported
by the raised TNF-a levels observed in non-transgenic
animals also given the antibody. These high levels of
TNF-a were present despite the absence of detectable
PfMSP119-specific IgA in the final bleeds (in contrast to
similar experiments with IgG1), confirming that the
half-life of the passively transferred human IgA in mice
is less than that for human IgG1. All animals given
PfMSP119-specific IgA (irrespective of genetic back-
ground), also made significant mouse anti-human IgA
responses on day 10 as assessed by ELISA (Additional
file 1, Figure S2), suggesting that the high levels of
inflammatory cytokines observed may be a consequence
of mounting an anti-human IgA immune response and
are not the result of malaria infection per se,a st h e s e
cytokines were not observed in challenged mice given
PBS.
Discussion
We describe the development of a fully human IgA with
specificity for a very well characterized epitope on
MSP119 from P. falciparum, useful for dissecting human
Figure 3 Course of a PfMSP119 transgenic P. berghei infection in mice. Groups of 3 (experiment 1) or 4 (experiment 2) FcaRI transgenic (Tg)
or nontransgenic (NTg) littermates were injected i.p. with a total dose of 1.5 mg human anti-PfMSP119 IgA (C1) or phosphate buffered saline
(PBS). No significant differences were observed for either the course of parasitemia or weight loss in both experiments. Each point represents the
geometric mean parasitemia or weight of mice in each group at the time after i.p. challenge with 5,000 parasitized erythrocytes. In experiment 2,
the FcaRI-blocking mAb 2H8 was co-administered at the same time as the IgA into CD89 Tg animals.
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malaria [3].
This novel IgA was generated from a human IgG1
mAb (C1), previously shown to protect human FcgRI
(CD64) transgenic mice (but not wild type animals)
from a lethal challenge with rodent malaria (P. berghei)
transgenic for the P. falciparum MSP119 (PfMSP119)
antigen [3]. The engineered IgA recognized parasites in
infected erythrocytes and bound PfMSP119 with compar-
able kinetics to that observed with the parental IgG1
from which it was derived. Despite triggering potent and
functional in vitro responses the IgA failed to protect
human FcaRI transgenic mice from a malaria infection.
Although the injected IgA is mostly monomeric, and
therefore binds transiently to FcaR, immune-complexes
formed on engaging PfMSP119 on merozoites would be
expected to bind avidly to FcaRI [1,2]. We also tried
without success to passively protect the CD89 transgenic
animals with sera from rabbits immunized with
PfMSP119 or plasma from vaccinated humans or
humans from endemic regions with significant levels of
anti-PfMSP119 human IgA antibodies by ELISA (data
not shown). This is noteworthy, as clinical protection
from P. falciparum malaria, has recently been shown to
correlate with neutrophil respiratory bursts induced by
merozoites opsonized with human serum antibodies
[24]. This important study demonstrated that immune
African sera depleted of IgG by protein-G Sepharose
chromatography (but presumably still containing IgA),
gave negligible activity in their antibody-dependent
respiratory burst assays (ADRB). Whilst highlighting an
absolute requirement for IgG, this finding is however
difficult to reconcile with the observed ability here of
PfMSP119-specific human IgA to induce very effective
luminol NADPH-oxidase mediated respiratory bursts
and degranulation from human blood neutrophils (Fig-
ure 2) [12,13].
One explanation for the failure of the IgA to protect
against malarial challenge may be that it is difficult for
IgA administered i.p. to leave the peritoneum and reach
the circulation and other parts of the body, where any
protective effects would presumably be mediated. Trans-
fer of IgG from peritoneum to other body compart-
ments may be assisted, at least in part, through
interaction with FcRn, an IgG receptor present on a
variety of cell types, capable of bidirectional transport
across epithelial surfaces and involved in control of IgG
turnover [25]. IgA, in contrast, is unable to bind FcRn,
and may be more reliant on diffusion to reach the circu-
lation and distribute within other body compartments.
This may also explain why recombinant IgA when admi-
nistered intra-nasally was particularly effective at con-
trolling tuberculosis [18].
Another explanation for the lack of in vivo efficacy
may be that the administered IgA was cleared very
rapidly from the mouse, before it had sufficient opportu-
nity to mediate any protective effects. Unlike humans,
where the half-life of the chiefly monomeric serum IgA
is approximately 4-5 days [26], in mice monomeric IgA
has a half-life of just 24 hours [27]. IgG is cleared much
more slowly due to interaction with FcRn, and therefore
when administered i.p. presumably has a much greater
opportunity for functional impact.
A third possibility is that the FcaRI in the transgenic
mice is not expressed on the cell types critical for pro-
tection at sufficiently high levels, or on a sufficient pro-
portion of these cells, or on cells located within the
required body compartment. For example, in contrast to
the situation in humans, only a subpopulation of the
monocytes of the transgenic mice express human FcaRI,
and peritoneal macrophages and platelets exhibit no
expression [19].
These three possibilities, taken together, suggest that
the FcaRI transgenic mouse, although undoubtedly the
best model currently available, may not afford the
means to fully assess the capability of human IgA to
offer protection in the human setting.
This is the first recombinant human IgA to target
PfMSP119. However, in exploring the role of IgA in
malaria, others have tested recombinant human IgA1
and IgA2 localized on the surface of polystyrene beads
in a two-step antibody-dependent cellular inhibition
(ADCI) assay [28]. In contrast to human IgG1 and IgG3,
Figure 4 Plasma TNF-a responses in animals given i.p.
PfMSP119-specific IgA. Each bar represents the mean
concentration of TNF-a ± SE from each group of mice in Fig. 3.
Levels of TNF-a are shown for CD89 Tg (Tg) animals passively
transferred with human IgA (closed circles) or PBS (open circles)
against non-transgenic (NTg) littermates also given IgA (closed
triangles) or PBS (open triangles). Each plasma sample was assayed
in triplicate determinations for each animal. Differences between
the groups were analyzed using Dunn’s multiple comparison test
and statistically significant differences are indicated.
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ADCI of malaria parasites by human monocytes [28].
Human monocytes express FcaRI and induce parasite
inhibitory TNF-a [29], and may therefore have been
expected to engage in ADCI. This finding is in keeping
with the lack of an in vivo effect seen here, the data sug-
gesting neutrophils rather than monocytes may fulfill
this role, and with either human IgA targeting the P.
berghei PfMSP119 transgenic, or earlier against P. yoelii
MSP119 [13]. However, it will be necessary to generate
epitope-matched murine IgAs (and IgGs) to determine
if mouse monocytes/neutrophils are capable of ADCI/
ADRB and whether mouse IgA can protect against
rodent malarias in vivo. Although no counterpart for
human FcaRI is known in mice, mouse macrophages do
bind mouse IgA, and Mac-2/galectin-3 (gal-3) has been
suggested to be the receptor involved [30]. Interestingly,
gal-3 is known to bind IgE, and there may be some
mileage in developing recombinant IgE to investigate
malaria infection, as mouse IgE can also bind FcgRIV
(which also binds IgG2a and IgG2b) on mouse mono-
cytes [31]. Intriguingly, murine IgE has been shown to
confer protection from P. berghei in C57BL/6 mice, and
elevated anti-malarial IgE in asymptomatic individuals
has been shown to associate with a reduced risk of sub-
sequent clinical malaria in humans [32].
We observed that a small proportion of mice given
the recombinant human IgA preparation in the context
of a malaria infection developed significant mouse
anti-human antibody responses (MAHA) with elevated
TNF-a within 10 days of the last IgA dose, which were
not observed in control animals challenged with
malaria (Figure 4). Our observations suggest that the
responses are not dependent on the presence of the
FcaRI transgene and therefore may represent a reac-
tion to the administered IgA itself. Further experi-
ments will be necessary to clarify whether the response
noted is peculiar to the particular IgA preparation
used which may contain undetected levels of aggre-
gates, or the specificity of the IgA for the co-adminis-
tered malarial parasite that might result in particular
cross-linking events, or is a general effect associated
with human IgA administration to mice in the absence
of malaria challenge infection.
Conclusions
In summary, a novel PfMSP119-specific IgA did not
show protective capability against parasite challenge in
mice transgenic for human FcaRI. While this finding
may indicate that IgA does not play a major role in pro-
tection against malaria, we cannot rule out the possibi-
lity that the findings reflect certain shortcomings of the
mouse model used. Thus important differences in IgA
half-life, IgA bio-distribution, and FcaRI expression
p r o f i l eb e t w e e nt h et r a n s g e n i cm i c ea n dh u m a n sm a y
have compromised the antibody’s ability to mediate pro-
tective effects, and further experimentation will be
r e q u i r e dt of u l l yd i s s e c tt h er o l eo fI g Ai nh u m a n
malaria.
Methods
Ethics Statement
Informed written consent was obtained from all partici-
pants and approval for the use of human samples was
obtained from the Ethical Committees at Nottingham
and Oxford. All animal experiments were approved by
the Home Office and performed in accordance with UK
guidelines and regulations (PPL 40/2753).
Construction of human IgA
T h ev a r i a b l eh e a v y( V H )g e n ef r o mp V H - C 1 - g1w a s
subcloned as a BssHII/BstEII fragment upstream of the
human IgA1 a-chain constant region sequence pre-
viously inserted into the mammalian expression vector
pcDNA3.1/Hygro (Invitrogen, UK), to create pVH-C1-
a1. Mammalian HEK293T cells (European Collection
of Cell Cultures) were co-transfected with linearized
pVH-C1-a1 and pVK-C1-Express (expression vector
containing the corresponding C1 variable light (VL)
chain upstream of the human C gene). Positive clones
secreting PfMSP119-specific IgA were detected by
enzyme-linked immunosorbent assay (ELISA) with
recombinant PfMSP119 coated plates and by immuno-
blotting with goat anti-human IgA Abs conjugated to
horseradish peroxidase (HRP) or alkaline phosphatase
(AP) as previously described [3,13]. Recombinant
PfMSP119 used in all ELISAs was generated as pre-
viously described [33]. From large-scale cultures,
human IgA was purified by affinity chromatography on
anti-human IgA agarose columns by FPLC (Sigma).
The integrity and purity of the antibodies was verified
by gel electrophoresis on both non-denaturing and
denaturing gels according to the manufacturer’s
instructions (Novex) (see Figure 1).
Luminol chemiluminescence assay of respiratory burst
and myeloperoxidase release
Neutrophils were isolated from heparinized blood
taken from healthy volunteers by sedimentation of ery-
throcytes in 6% (w/v) dextran T70 (GE Healthcare, U.
K.) in 0.9% (w/v) saline at 37°C for 30 min, followed
by leukocyte separation on a discontinuous density
gradient of Lymphoprep (r = 1.077 g/cm
3;N y c o m e d ,
Birmingham, UK) over Ficoll-Hypaque (r =1 . 1 1 9g /
cm
3), centrifuged at 700 × g for 20 min at room tem-
perature. Approval for the collection and use
of human cells was obtained from the local Queen’s
Medical Centre ethical committee. Wells of
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Laboratories, Billinghurst, Sussex, UK) were coated
with 150 μlo fPfMSP119 at 5 μgm l
-1 or 50 μgo fI g A
in coating buffer (0.1 M carbonate buffer, pH 9.6) and
incubated overnight at 4°C. After washing three times
with PBS, 150 μlo fa n t i - PfMSP119 IgA at 50 μgm l
-1
was added to antigen coated wells. In each case, tripli-
cate wells were prepared and left for 2 h at room tem-
perature. After washing as before, 100 μlo fl u m i n o l
[67 μgm l
-1 in Hank’s buffered saline solution (HBSS)
containing 20 mM HEPES and 0.1 g/100 ml globulin-
free BSA (HBSS/BSA)] were added to each well. After
the addition of 50 μl of purified neutrophils (10
6/ml in
HBSS/BSA) to each well, plates were transferred to a
Microlumat LB96P luminometer, and the chemilumi-
nescence measured at 2 min intervals for 120 min at
37°C. Data were analyzed using Excel software.
Cytokines
Concentrations of GM-CSF, IFN-g,I L - 1 a,I L - 2 ,I L - 4 ,
IL-5, IL-6, IL-10, IL-17 and TNF-a in individual mouse
sera were determined by flow cytometry using the Flow-
Cytomix mouse Th1/Th2 10plex (BMS820FF) bead kit
against known standard curves and according to manu-
facturer’s instructions (Bender MedSystems). Beads were
analyzed using a Beckman Coulter EPICS ALTRA flow
cytometer (High Wycombe, Bucks, UK) and data
analyzed with Bender MedSystems software.
Passive immunization and parasite challenge
Because of the lack of an animal model for P. falci-
parum and because mice do not express a homologue
of human FcaRI, human FcaRI transgenic mice have
been developed that express FcaRI on blood neutro-
phils and a proportion of their monocytes [Additional
file 1, Figure 1 [22]]. Transgenic (Tg) Balb/c × Balb/c
F1 mice 9-12 wks old and bred under specific patho-
gen-free conditions were used. Non-transgenic (NTg)
littermates served as controls. Mice were screened for
FcaRI expression by PCR of whole blood using for-
ward (5’-TGGGGCTTCGCACAGGGTCTTTA-3’)a n d
reverse (5’-CCAGCACACCGCAGTCGCCATAC-3’)
primers for human CD89, and by analysis of lysed
whole blood on a FAC-Scan with PE-conjugated anti-
human FcaRI (Additional file 1). PfMSP119-specific
IgA (at 0.5 mg/injection) with or without 50 μg/injec-
tion blocking mAb 2H8 (mouse IgG1 anti-human
FcaRI) [23] was administered intraperitoneally (i.p.) on
days -1, 0 and day +1 with respect to parasite chal-
lenge. Parasitized erythrocytes (5000/mouse) derived
f r o mp a s s a g e dm i c ei n f e c t e dw i t hP. berghei parasites
transgenic for P. falciparum MSP119 were injected i.p.
at least 3 h after antibody treatment on day 0 as
previously described [3,13]. Parasitemia was assessed
daily on Giemsa reagent-stained blood smears.
Additional material
Additional file 1: Characterization of CD89 transgenic mice. FACS
analysis of gated whole blood from CD89 negative or positive animals as
assessed by PCR [19]. Gated neutrophils (R3, blue) and blood monocytes
(R2, green) from positive animals used in this study bind PE-conjugated
anti-human CD89 while those of CD89-negative animals do not. Anti-
human IgA responses are provoked in mice passively administered with
recombinant human IgA.
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